Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2006-05-22 15:12:37 UTC |
---|
Update Date | 2022-03-07 02:49:18 UTC |
---|
HMDB ID | HMDB0003166 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | 16b-Hydroxystanozolol |
---|
Description | 16b-Hydroxystanozolol is the major metabolite of stanozolol. Stanozolol is an anabolic steroid illicitly used for growth promoting purposes in animal production. For reasons of public health the use of anabolic steroids as growth promoters is officially banned in Europe in animals intended for consumption. Stanozolol is an anabolic steroid banned in competing athletes. Doping control screening for the analysis of anabolic steroids in human urine or the detection of anabolic steroid residues in cattle's urine is achieved using liquid and gas chromatography time-of-flight mass spectrometry, liquid chromatography-tandem mass spectrometry or through a combination of liquid chromatography/tandem mass spectrometry and gas chromatography/mass spectrometry. Androgenic anabolic steroids are defined as natural, synthetic or semi-synthetic drugs chemicals derived from testosterone, used with the aim to improve physical performance by increasing both muscle strength and mass. Despite their reported toxicological effects on the cardiovascular, hepatic and neuro-endocrine systems, the AAS have been extensively used in sports activities. (PMID: 15782394 , 17610244 , 17724580 ). |
---|
Structure | [H][C@@]12C[C@H](O)[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC3=C(C[C@]12C)C=NN3 InChI=1S/C21H32N2O2/c1-19-10-12-11-22-23-17(12)8-13(19)4-5-14-15(19)6-7-20(2)16(14)9-18(24)21(20,3)25/h11,13-16,18,24-25H,4-10H2,1-3H3,(H,22,23)/t13-,14+,15-,16-,18-,19-,20-,21-/m0/s1 |
---|
Synonyms | Value | Source |
---|
(5a,16b,17b)-17-Methyl-'h-androst-2-eno[3,2-c]pyrazole-16,17-diol | HMDB | 16b-OH-Stanozolol | HMDB | 16beta-Hydroxystanozolol | HMDB | Cyclopenta[7,8]phenanthro[2,3-c]pyrazole, 2'H-androst-2-eno[3,2-c]pyrazole-16,17-diol deriv. | HMDB | 16-Hydroxystanozolol, (5alpha,16alpha,17beta)-isomer | HMDB | 16-Hydroxystanozolol | HMDB | 16-Hydroxystanozolol, (5alpha,16alpha,17alpha)-isomer | HMDB |
|
---|
Chemical Formula | C21H32N2O2 |
---|
Average Molecular Weight | 344.491 |
---|
Monoisotopic Molecular Weight | 344.246378278 |
---|
IUPAC Name | (1S,2S,10S,13R,14S,16S,17R,18S)-2,17,18-trimethyl-6,7-diazapentacyclo[11.7.0.0²,¹⁰.0⁴,⁸.0¹⁴,¹⁸]icosa-4(8),5-diene-16,17-diol |
---|
Traditional Name | (1S,2S,10S,13R,14S,16S,17R,18S)-2,17,18-trimethyl-6,7-diazapentacyclo[11.7.0.0²,¹⁰.0⁴,⁸.0¹⁴,¹⁸]icosa-4(8),5-diene-16,17-diol |
---|
CAS Registry Number | 125590-76-3 |
---|
SMILES | [H][C@@]12C[C@H](O)[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC3=C(C[C@]12C)C=NN3 |
---|
InChI Identifier | InChI=1S/C21H32N2O2/c1-19-10-12-11-22-23-17(12)8-13(19)4-5-14-15(19)6-7-20(2)16(14)9-18(24)21(20,3)25/h11,13-16,18,24-25H,4-10H2,1-3H3,(H,22,23)/t13-,14+,15-,16-,18-,19-,20-,21-/m0/s1 |
---|
InChI Key | IZGBPAAEPVNBGA-BWPSUJIGSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as estrane steroids. These are steroids with a structure based on the estrane skeleton. |
---|
Kingdom | Organic compounds |
---|
Super Class | Lipids and lipid-like molecules |
---|
Class | Steroids and steroid derivatives |
---|
Sub Class | Estrane steroids |
---|
Direct Parent | Estrane steroids |
---|
Alternative Parents | |
---|
Substituents | - Estrane-skeleton
- Hydroxysteroid
- 16-beta-hydroxysteroid
- 16-hydroxysteroid
- 17-hydroxysteroid
- Azole
- Cyclic alcohol
- Pyrazole
- Tertiary alcohol
- Heteroaromatic compound
- 1,2-diol
- Secondary alcohol
- Organoheterocyclic compound
- Azacycle
- Organooxygen compound
- Organonitrogen compound
- Organic oxygen compound
- Organic nitrogen compound
- Organopnictogen compound
- Hydrocarbon derivative
- Alcohol
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | Not Available |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | |
---|
Role | |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | 2.801 | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
16b-Hydroxystanozolol,1TMS,isomer #1 | C[C@]12CC3=C(C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1C[C@H](O[Si](C)(C)C)[C@]2(C)O)[NH]N=C3 | 3215.3 | Semi standard non polar | 33892256 | 16b-Hydroxystanozolol,1TMS,isomer #2 | C[C@]12CC3=C(C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1C[C@H](O)[C@]2(C)O[Si](C)(C)C)[NH]N=C3 | 3224.1 | Semi standard non polar | 33892256 | 16b-Hydroxystanozolol,1TMS,isomer #3 | C[C@]12CC3=C(C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1C[C@H](O)[C@]2(C)O)N([Si](C)(C)C)N=C3 | 3238.4 | Semi standard non polar | 33892256 | 16b-Hydroxystanozolol,2TMS,isomer #1 | C[C@]12CC3=C(C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1C[C@H](O[Si](C)(C)C)[C@]2(C)O[Si](C)(C)C)[NH]N=C3 | 3266.1 | Semi standard non polar | 33892256 | 16b-Hydroxystanozolol,2TMS,isomer #2 | C[C@]12CC3=C(C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1C[C@H](O[Si](C)(C)C)[C@]2(C)O)N([Si](C)(C)C)N=C3 | 3243.7 | Semi standard non polar | 33892256 | 16b-Hydroxystanozolol,2TMS,isomer #3 | C[C@]12CC3=C(C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1C[C@H](O)[C@]2(C)O[Si](C)(C)C)N([Si](C)(C)C)N=C3 | 3230.8 | Semi standard non polar | 33892256 | 16b-Hydroxystanozolol,3TMS,isomer #1 | C[C@]12CC3=C(C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1C[C@H](O[Si](C)(C)C)[C@]2(C)O[Si](C)(C)C)N([Si](C)(C)C)N=C3 | 3288.4 | Semi standard non polar | 33892256 | 16b-Hydroxystanozolol,3TMS,isomer #1 | C[C@]12CC3=C(C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1C[C@H](O[Si](C)(C)C)[C@]2(C)O[Si](C)(C)C)N([Si](C)(C)C)N=C3 | 3267.9 | Standard non polar | 33892256 | 16b-Hydroxystanozolol,3TMS,isomer #1 | C[C@]12CC3=C(C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1C[C@H](O[Si](C)(C)C)[C@]2(C)O[Si](C)(C)C)N([Si](C)(C)C)N=C3 | 3363.2 | Standard polar | 33892256 | 16b-Hydroxystanozolol,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)O[C@H]1C[C@H]2[C@@H]3CC[C@H]4CC5=C(C=N[NH]5)C[C@]4(C)[C@H]3CC[C@]2(C)[C@@]1(C)O | 3470.8 | Semi standard non polar | 33892256 | 16b-Hydroxystanozolol,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)O[C@@]1(C)[C@@H](O)C[C@H]2[C@@H]3CC[C@H]4CC5=C(C=N[NH]5)C[C@]4(C)[C@H]3CC[C@@]21C | 3476.7 | Semi standard non polar | 33892256 | 16b-Hydroxystanozolol,1TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)N1N=CC2=C1C[C@@H]1CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H](O)[C@]4(C)O)[C@@]1(C)C2 | 3455.5 | Semi standard non polar | 33892256 | 16b-Hydroxystanozolol,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)O[C@H]1C[C@H]2[C@@H]3CC[C@H]4CC5=C(C=N[NH]5)C[C@]4(C)[C@H]3CC[C@]2(C)[C@@]1(C)O[Si](C)(C)C(C)(C)C | 3758.8 | Semi standard non polar | 33892256 | 16b-Hydroxystanozolol,2TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)O[C@H]1C[C@H]2[C@@H]3CC[C@H]4CC5=C(C=NN5[Si](C)(C)C(C)(C)C)C[C@]4(C)[C@H]3CC[C@]2(C)[C@@]1(C)O | 3678.0 | Semi standard non polar | 33892256 | 16b-Hydroxystanozolol,2TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)O[C@@]1(C)[C@@H](O)C[C@H]2[C@@H]3CC[C@H]4CC5=C(C=NN5[Si](C)(C)C(C)(C)C)C[C@]4(C)[C@H]3CC[C@@]21C | 3666.1 | Semi standard non polar | 33892256 | 16b-Hydroxystanozolol,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)O[C@H]1C[C@H]2[C@@H]3CC[C@H]4CC5=C(C=NN5[Si](C)(C)C(C)(C)C)C[C@]4(C)[C@H]3CC[C@]2(C)[C@@]1(C)O[Si](C)(C)C(C)(C)C | 3920.9 | Semi standard non polar | 33892256 | 16b-Hydroxystanozolol,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)O[C@H]1C[C@H]2[C@@H]3CC[C@H]4CC5=C(C=NN5[Si](C)(C)C(C)(C)C)C[C@]4(C)[C@H]3CC[C@]2(C)[C@@]1(C)O[Si](C)(C)C(C)(C)C | 4035.8 | Standard non polar | 33892256 | 16b-Hydroxystanozolol,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)O[C@H]1C[C@H]2[C@@H]3CC[C@H]4CC5=C(C=NN5[Si](C)(C)C(C)(C)C)C[C@]4(C)[C@H]3CC[C@]2(C)[C@@]1(C)O[Si](C)(C)C(C)(C)C | 3610.3 | Standard polar | 33892256 |
|
---|
General References | - Masse R, Ayotte C, Bi HG, Dugal R: Studies on anabolic steroids. III. Detection and characterization of stanozolol urinary metabolites in humans by gas chromatography-mass spectrometry. J Chromatogr. 1989 Dec 29;497:17-37. [PubMed:2625454 ]
- Georgakopoulos CG, Vonaparti A, Stamou M, Kiousi P, Lyris E, Angelis YS, Tsoupras G, Wuest B, Nielen MW, Panderi I, Koupparis M: Preventive doping control analysis: liquid and gas chromatography time-of-flight mass spectrometry for detection of designer steroids. Rapid Commun Mass Spectrom. 2007;21(15):2439-46. [PubMed:17610244 ]
- Pozo OJ, Van Eenoo P, Deventer K, Delbeke FT: Development and validation of a qualitative screening method for the detection of exogenous anabolic steroids in urine by liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem. 2007 Oct;389(4):1209-24. Epub 2007 Aug 28. [PubMed:17724580 ]
- Van Poucke C, Van De Velde M, Van Peteghem C: Combination of liquid chromatography/tandem mass spectrometry and gas chromatography/mass spectrometry for the detection of 21 anabolic steroid residues in bovine urine. J Mass Spectrom. 2005 Jun;40(6):731-8. [PubMed:15782394 ]
|
---|